Semax

II. What is this compound?

Semax's story starts in 1980s Russia, where researchers were hunting for a way to keep cognitive function steady and protect the brain after stress and hypoxia. Their answer was a synthetic heptapeptide: a seven-amino-acid slice of ACTH's N-terminal portion, modified to add a methionine group.

The result is the sequence Met-Glu-His-Phe-Pro-Gly-Pro — a heptapeptide of just 813.9 daltons built to mimic ACTH(4-10), with an N-terminal methionine tied directly to bioactivity. It's a deceptively simple construction for a molecule with this much research attention.

First, the practical physics: Semax's half-life is short — measured in minutes — which is all the more curious because its studied effects are anything but fleeting. So researchers had to be clever about delivery.

That cleverness took two forms: intranasal and subcutaneous administration. The nasal spray formulation is the more interesting — research suggests it extends local bioavailability, letting the peptide reach neural tissue while keeping systemic exposure low.

Human data exist, but they're shaped by a specific research tradition: clinical studies in cerebrovascular care documented preserved neurological function in the acute period of ischemic stroke [2] PMID: 10358912 . Cognitive and mood findings, by contrast, still rest mostly on preclinical work.

Which raises the question behind that half-life: how does a molecule gone in minutes end up influencing memory? Studies indicate Semax enhances BDNF expression and TrkB signaling in the brain [3] PMID: 16996699 , hinting that a short-lived peptide may talk to long-lived systems.

Here's the frame for everything that follows: in the US, EU, and UK, Semax is classified for research use only — a research compound, not an approved therapeutic. What it does inside that frame — human clinical data for cognition, preclinical leads for neuroprotection and mood — is what the mechanism and evidence sections unpack next.

III. How it works

• BDNF expression enhancement in hippocampus and cortex
  PMID 21833148PMID 25313017
• TrkB receptor activation promoting neuroplasticity
  PMID 21833148
• Modulation of serotonin and dopamine neurotransmitter systems
  PMID 25313017

IV. Research Findings

• cognitive-enhancement clinical
  PMID 21833148PMID 25313017
• neuroprotection preclinical
  PMID 21833148
• mood-support preclinical
  PMID 25313017

V. Dosage Context Explained

• Administration Routes

  intranasal

  Range

  0.1–1 mg/day

  clinical studies for cognitive impairment and optic nerve atrophy

  PMID 25313017

VI. Side Effects: Research Context

• nasal irritation (with spray formulation)
• transient headache
• mild anxiety at higher doses (anecdotal)